Late-stage human African trypanosomiasis in a Sudanese refugee

Medical Journal of Australia

Volumn 192, Issue 7, 2010, Pages 417-419

  Cherian, Paul ^a   Junckerstorff, Ralph K ^a   Rosen, David ^a   Kumarasinghe, Prasad ^a   Morling, Alan ^a   Tuch, Philip ^a   Raven, Sonja ^a   Murray, Ronan J ^a,b   Heath, Christopher H ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; EFLORNITHINE; GADOLINIUM; HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN; ANTITRYPANOSOMAL AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AFRICAN TRYPANOSOMIASIS; APATHY; ARTICLE; CACHEXIA; CASE REPORT; CENTRIFUGATION; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC ACCURACY; DROWSINESS; ELECTROENCEPHALOGRAM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPIGMENTATION; IMMUNOFLUORESCENCE TEST; IMMUNOGLOBULIN BLOOD LEVEL; LETHARGY; LICHENOID; MICROCYTIC ANEMIA; NEURODERMATITIS; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PAPULE; PROTEIN BLOOD LEVEL; PRURIGO; REFUGEE; SEIZURE; SKIN BIOPSY; SKIN PRURITUS; SUDAN; TRYPANOSOMA BRUCEI; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION; AUSTRALIA; CEREBROSPINAL FLUID; ETHNOLOGY; ISOLATION AND PURIFICATION; PARASITOLOGY;

AUSTRALIA; CEREBROSPINAL FLUID; EFLORNITHINE; FEMALE; HUMANS; REFUGEES; SUDAN; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN; YOUNG ADULT;

EID: 77951919813     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03569.x     Document Type: Article

References (15)

1. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet 2010; 375: 148-159. Epub ahead of print 14 Oct 2009.
2. Njiru ZK, Mikosza AS, Matovu E, et al. African trypanosomiasis: sensitive and rapid detection of the sub-genus Trypanozoon by loop-mediated isothermal amplification (LAMP) of parasite DNA. Int J Parasitol 2008; 38: 589-599. (Pubitemid 351284472)
3. Burri C, Brun R. Human African trypanosomiasis. In: Cook GC, Zumla AI, editors. Manson's tropical diseases. 21st ed. Edinburgh: Elsevier, 2003: 1303-1323.
4. World Health Organization. Control and surveillance of African trypanosomiasis. Report of WHO expert committee. World Health Organ Tech Rep Ser 1998; 881: I-VI, 1-114.
5. Brun R, Balmer O. New developments in human African trypanosomiasis. Curr Opin Infect Dis 2006; 19: 415-420. (Pubitemid 44338099)
6. Picozzi K, Fevre E, Odiit M, et al. Sleeping sickness in Uganda: a thin line between two fatal diseases. BMJ 2005; 331: 1238-1242.
7. Lejon V, Boelaert M, Jannin J, et al. The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa. Lancet Infect Dis 2003; 3: 804-808. (Pubitemid 37489964)
8. Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006; 97: 55-64. (Pubitemid 41758517)
9. Chappuis F, Loutan L, Simarro P, et al. Options for field diagnosis of human African trypanosomiasis. Clin Microbiol Rev 2005; 18: 133-146. (Pubitemid 40170665)
10. Cattand P, Miezan BT, de Raadt P. Human African trypanosomiasis: use of double centrifugation of cerebrospinal fluid to detect trypanosomes. Bull World Health Organ 1988; 66: 83-86.
11. Lejon V, Büscher P. Cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post treatment follow up. Trop Med Int Health 2005; 10: 395-403.
12. Chappuis F, Udayraj N, Stietenroth K, et al. Eflornithine is safer than melarsoprol for the treatment of second stage Trypanosoma brucei gambiense human African trypanosomiasis. Clin Infect Dis 2005; 41: 748-751.
13. Priotto G, Pinoges L, Fursa I, et al. Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. BMJ 2008; 336: 705-708.
14. Priotto G, Kasparian S, Mutambo W, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 2009; 374: 56-64.
15. World Health Organization. Report of the 17th expert committee on the selection and use of essential medicines. 23 to 27 March 2009. WHO Technical Report Series (12 February 2010). Geneva: WHO, 2010: 43-44. http://www.who.int/ selection-medicines/committees/expert/17/WEB-TRS-DEC-2009.pdf (accessed Feb 2010).